Lumateperone as Adjunct Therapy for Major Depressive Disorder
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 3rd, 2025
|
Major depressive disorder (MDD) is a highly prevalent condition that profoundly affects quality of life, yet standard antidepressant treatment achieves remission in only about half of patients. Efforts to enhance efficacy with adjunctive antipsychotics have been limited by poor tolerability and high rates of treatment discontinuation. To address this, Johnson & Johnson funded a study evaluating lumateperone, a novel antipsychotic, as an adjunct to traditional antidepressants in the management of major depressive disorder.
The phase 3 clinical trial enrolled 484 participants with a mean age of 45 years, all diagnosed with major depressive disorder according to DSM-5 criteria. Two-thirds of the participants were women, with an average of 3.6 prior depressive episodes. Baseline scores included a physician-rated MADRS of 30.2, a patient-rated QIDS-SR-16 of 17.8, and a GAD-7 of 9.7. Most patients were receiving selective serotonin reuptake inhibitors (69%), followed by selective norepinephrine reuptake inhibitors (24%).
Participants were randomized to receive either placebo or 42 mg of lumateperone in addition to their current antidepressant regimen. Lumateperone, already approved for schizophrenia and bipolar depression, acts primarily as a 5-HT2A antagonist and modulates dopamine, glutamate, and aspartate signaling. Its side effect profile is expected to be more favorable, given minimal activity on muscarinic and 5-HT2C receptors.
After 43 days of treatment, patients receiving lumateperone demonstrated significantly greater clinical improvement than placebo, as reflected by reductions in both MADRS and QIDS-SR-16 scores. Notably, benefits were observed as early as day 8, with higher overall remission rates in the lumateperone group. Although adverse effects such as dry mouth, fatigue, and tremor were more frequent, there was no significant increase in metabolic risk or weight gain. The authors suggest that future studies should include patients with treatment-resistant depression, elevated suicide risk, or comorbid psychiatric conditions to further define the role of lumateperone in clinical practice.
The phase 3 clinical trial enrolled 484 participants with a mean age of 45 years, all diagnosed with major depressive disorder according to DSM-5 criteria. Two-thirds of the participants were women, with an average of 3.6 prior depressive episodes. Baseline scores included a physician-rated MADRS of 30.2, a patient-rated QIDS-SR-16 of 17.8, and a GAD-7 of 9.7. Most patients were receiving selective serotonin reuptake inhibitors (69%), followed by selective norepinephrine reuptake inhibitors (24%).
Participants were randomized to receive either placebo or 42 mg of lumateperone in addition to their current antidepressant regimen. Lumateperone, already approved for schizophrenia and bipolar depression, acts primarily as a 5-HT2A antagonist and modulates dopamine, glutamate, and aspartate signaling. Its side effect profile is expected to be more favorable, given minimal activity on muscarinic and 5-HT2C receptors.
After 43 days of treatment, patients receiving lumateperone demonstrated significantly greater clinical improvement than placebo, as reflected by reductions in both MADRS and QIDS-SR-16 scores. Notably, benefits were observed as early as day 8, with higher overall remission rates in the lumateperone group. Although adverse effects such as dry mouth, fatigue, and tremor were more frequent, there was no significant increase in metabolic risk or weight gain. The authors suggest that future studies should include patients with treatment-resistant depression, elevated suicide risk, or comorbid psychiatric conditions to further define the role of lumateperone in clinical practice.